{
}
UBS has lowered its price target for Neurocrine Biosciences to $137 from $154 while maintaining a Buy rating, citing a reevaluation of biotech stocks amid market trends. The company, known for its neurological treatments, has seen a 24.6% decline year-to-date but is viewed as undervalued, with strong revenue growth and solid financial health. Recent developments include the appointment of Dr. Sanjay Keswani as Chief Medical Officer and promising results from a study on Ingrezza, which showed significant remission rates for tardive dyskinesia symptoms.
UBS has lowered its price target for Neurocrine Biosciences to $137 while maintaining a Buy rating, citing a favorable risk/reward ratio and the absence of regulatory risks. The company’s lead product, Ingrezza, shows strong sales growth, although challenges in payer coverage may impact demand. Recent clinical trial results indicate promising long-term remission rates for tardive dyskinesia, while leadership changes and cautious revenue estimates reflect the evolving landscape for Neurocrine.
UBS analyst Ashwani Verma has lowered the price target for Neurocrine Biosciences (NBIX) to $137. This adjustment reflects the latest insights and market conditions affecting the company's stock performance.
UBS analyst Ashwani Verma has maintained a Neutral rating on Royalty Pharma (NASDAQ: RPRX) with a price target of $33.00. The reiteration reflects the analyst's assessment of the company's current market position.
UBS has upgraded Jazz Pharmaceuticals' stock rating from Neutral to Buy, raising the price target to $179 from $145, citing confidence in the company's base business and the Ziihera pipeline. The firm anticipates a 7.0x P/E multiple, supported by strong earnings projections and a robust financial health score. Jazz reported Q4 2024 earnings of $6.60 per share, exceeding expectations, and plans to acquire Chimerix for $935 million, aligning with its promising treatment pipeline.
UBS has upgraded Jazz Pharmaceuticals to a Buy rating, raising the price target from $145 to $179, citing confidence in its core business and the Ziihera pipeline's potential. The company boasts a gross profit margin of 92.4% and is considered undervalued, with analysts revising earnings expectations upward for the coming years. Despite some challenges, Jazz continues to perform strongly, particularly in its sleep and oncology segments, and is forecasting sales growth of 5% for 2025.
Ashwani Verma
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs lowers neurocrine biosciences stock target while maintaining buy rating
United States Dollar
Teva Pharmaceutical Industries Ltd
Neurocrine Biosciences, Inc.
USA
Ashwani Verma
Eiry W. Roberts
Sanjay Keswani
Show more
17:47 04.04.2025
ubs lowers neurocrine biosciences price target but maintains buy rating
United States Dollar
Teva Pharmaceutical Industries Ltd
Neurocrine Biosciences, Inc.
USA
Ashwani Verma
Eiry W. Roberts
Sanjay Keswani
Show more
17:29 04.04.2025
Neurocrine Biosciences price target reduced to 137 by UBS analyst
16:45 04.04.2025
ubs maintains neutral rating and price target for royalty pharma
14:26 27.03.2025
ubs upgrades jazz pharmaceuticals to buy with target price of 179 dollars
12:28 07.03.2025
ubs upgrades jazz pharmaceuticals to buy with price target raised to 179 dollars
11:51 07.03.2025
Trending
Subcategory
Industry Trends
Corporate News
Startups & Entrepreneurship
Global Trade Developments
Retail and Consumer Goods
Supply Chain Management
Government Economic Policies
Workplace Trends
Industry Mergers & Acquisitions
Stock Market Updates
Fintech Startups
Venture Capital Investments
Financial Scams and Security
Finance Mergers & Acquisitions
CEO Changes
Cryptocurrency Trends
Emerging Startups
Cryptocurrency & Blockchain Regulations
Funding Rounds & Investments
Energy Sector Developments
Countries:
Companies:
Apple Inc.
Google Inc.
Alphabet Inc.
NVIDIA Corporation
Tesla, Inc.
Microsoft Corporation
Amazon.com, Inc.
Delhivery Limited
Ecom Express Ltd.
Foxconn Technology Co., Ltd.
Samsung SDI Co., Ltd.
SWIGGY LIMITED
UWS JP Morgan EM A OSB
Netflix, Inc.
Airbnb, Inc.
Adobe Inc.
GEELY AUTO
TENCENT
CarTrade Tech Limited
Concrete Credit Limited
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
Japanese Yen
South Korean Won
Algerian Dinar
Vietnamese Đồng
Indonesian Rupiah
Australian Dollar
Egyptian Pound
Saudi Riyal
Swiss Franc
British Pound Sterling
Russian Ruble
Pakistani Rupee
People: